2seventy Bio, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.2seventybio.com

Moat Score

Market Cap $181.84M
PE -2
Debt $NaN
Cash $60.35M
EV $NaN
FCF -$140.90M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$94.55M
EBIT	-$94.55M
ROE	-41%
ROA	-19%
FCF	-$140.90M
Equity	$228.10M
Growth Stability	1
PE	-1.92
PB	0.8
P/FCF	-1.29
P/S	3.99
Price/Cash	0.33
Net Margins	-108%
Gross Margins	100%
Op. Margins	-207%
Sales Growth YoY	12%
Sales Growth QoQ	51%
Sales CAGR	-5%
Equity CAGR	46%
Earnings Growth YoY	-86%

Earnings Growth QoQ	-140%
Sales CAGR 5Y	-5%
Equity CAGR 5Y	46%
Earnings CAGR 3Y	5%
Sales CAGR 3Y	5%
Equity CAGR 3Y	-20%
Market Cap	$181.84M
Revenue	$45.62M
Assets	$503.85M
Cash	$60.35M
Shares Outstanding	51.51M
Moat Score	2%
Working Capital	174.38M
Current Ratio	4.95
Gross Profit	$45.62M
Shares Growth 3y	33%
Equity Growth QoQ	-3%
Equity Growth YoY	-26%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

SEC Filings

Direct access to 2seventy Bio, Inc. (TSVT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 2seventy Bio, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 2seventy Bio, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

2seventy Bio, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for 2seventy Bio, Inc..

Years

Calculation mode

= -$1.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$141M	-$1.4B
DCF		-$128M	-$116M	-$106M	-$96M	-$87M	-$80M	-$72M	-$66M	-$60M	-$54M	-$543M
Value	-$1.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-724%	-48%	-536%	-278%	-217%	-108%
ROA	-	-	-38%	-39%	-38%	-19%
ROE	-	-	-81%	-82%	-85%	-41%

Bad Net Margins (-107.99%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	460%	-78%	68%	10%	-5%
Earnings YoY growth	-	-63%	143%	-13%	-14%	-
Equity YoY growth	-	71%	382%	-14%	-18%	46%
FCF YoY growth	-	-66%	143%	19%	-30%	-